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Acid-base homeostasis during chronic PTH excess in humans. The
chronic renal and systemic acid-base effects of hyperparathyroidism in
humans remain controversial and unresolved. The present studies
evaluated the acid-base response of normal human subjects to a 13-day
intravenous infusion of synthetic b(1—34) PTH sufficient to result in
sustained hypercalcemia and hypophosphatemia. The acid-base re-
sponse was biphasic: an initial transient renal acidosis developed on the
first day of PTH infusion, followed by a prompt increase in net acid
excretion and plasma [HC03] of sufficient magnitude to result in a
steady state of mild metabolic alkalosis. The results indicate that: 1)
sustained, continuous, experimentally produced hyperparathyroidism
results in a steady state of mild metabolic alkalosis; 2) the alkalosis is
both generated and maintained, at least in part, by renal mechanisms;
and 3) reported renal acidosis in sustained clinical conditions of primary
hyperparathyroidism is not attributable to either direct or indirect
effects of PTH excess when present for a 2-week period, an interval
sufficient to re-establish a new steady state of renal and systemic
acid-base equilibrium.
Homéostasie acido-basique pendant un excès chronique de PTH chez
I'homme. Les effets acido-basiques rénaux et systémiques de
I'hyperparathyroIdisme chez l'homme sont sujets a controverse et
restent non résolus. Ces etudes ont évalué Ia réponse acido-basique de
sujets humains normaux a une perfusion intraveineuse de 13 jours de
b(l—34) PTH synthétique suffisante pour induire une hypercalcémie et
une hypophosphatémie prolongées. La réponse acido-basique était
biphasique: une acidose rénale transitoire initiale se développait le
premier jour de Ia perfusion de PTH, suivie par une élévation rapide de
l'excrdtion nette d'acides et du [HCO3] plasmatique d'importance
suffisante pour entralner a l'équilibre une alcalose metabolique
modérée. Ces résultats indiquent que: 1) une hyperparathyroIdie
soutenue, continue, produite expérimentalement, entraine une alcalose
métabolique moddrée; 2) l'alcalose est génerée et maintenue, au mains
en partie, par des mécanismes rénaux; 3) I'acidose rénale rapportee
dans des conditions cliniques d'hyperparathyroIdie primitive prolongee
n'est pas attribuable a des effets directs ou indirects de l'excès de PTH
lorsqu'il est present sur une période de deux semaines, un intervalle
suffisant pour ré-établir un nouvel état d'équilibre acido-basique renal et
systémique.
Hyperchloremic metabolic acidosis has been reported in
clinical states of primary hyperparathyroidism [1—51. There is
disagreement, however, whether this association is frequent or
not [51. These clinical observations have stimulated physiologic
investigations of acute PTH administration, which indicate
uniformly that large doses of the hormone suppress proximal
tubular bicarbonate reabsorption [6—101. Evidence has been
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adduced also that acute PTH administration, by mobilizing
skeletal alkali, enhances extrarenal buffering of infused mineral
acid loads [11, 121. Thus, the finding in both humans and dogs
that acute administration of large amounts of PTH results in
bicarbonaturia and decreased net acid excretion does not
resolve whether the renal response to PTH reflects augmented
extrarenal alkali input to ECF or impaired renal acidification.
The issue is rendered more complex by the finding in rats that
acute PTH administration results in an increase in renal net acid
excretion coupled with impaired superficial proximal bicarbon-
ate reabsorptive rates [61.
In addition to primary renal and extrarenal effects of PTH on
acid-base metabolism, a number of consequences of prolonged
PTH hypersecretion might account, in part, for the observed
variation in systemic acid-base homeostasis observed in clinical
primary hyperparathyroidism. PTH-induced phosphate deple-
tion, nephrocalcinosis, renal insufficiency, increased cytosolic
calcium, and hypertensive nephrosclerosis are potential renal
acidosis-producing factors [1, 2]. PTH-induced elevation in
plasma calcium concentration is a potential metabolic alkalosis-
producing factor [1, 2].
Chronic PTH administration (1 to 2 weeks) in dogs has been
reported recently to result in metabolic alkalosis, due in part to
renal mechanisms [13, 14]. The present studies evaluate the
chronic acid-base effects of PTH excess in human subjects
under conditions that define the known factors that might
influence systemic acid-base equilibrium.
Methods
The effect of chronic PTH infusion on plasma and urinary
acid-base and electrolyte composition was evaluated in chronic
balance studies carried out in four normal male human volun-
teers (ages 23 to 35, wt 68 to 79 kg). Each subject ingested a
constant amount of a whole food diet. The diet composition,
based on 70.0 kg/subject/24 hr, was: calories, 2660; N, 13.1 g;
fat, 63.6 g; carbohydrate, 439.9 g; Nat, 21.7 mEq; K, 109.7
mEq; Ca, 443 mg; 286 mg; phosphorus, 973 mg; and
total fluid, 4330 ml. The daily diet was supplemented in each
subject with three CaCO3 tablets (650 mg, Lilly, Indianapolis,
Indiana, USA), raising the Ca intake for a 70.0 kg individual
to 1220 rng/24 hr. All subjects ingested an identical amount of
each dietary constituent per kilogram body wt. Each subject
received a dietary NaC1 supplement (1.49 mmoles/kg/24 hr),
raising the total Na intake to 126.0 mEq/24 hr/70 kg. Fasting,
8:00A.M., heparinized, arterialized venous blood samples were
obtained at 24- to 48-hr intervals from a heated superficial hand
vein. Studies were carried out under metabolic balance condi-
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Table 1. Effect of chronic PTH infusion on plasma acid-base and electrolyte composition in human subjects (N = 4)
Anion
Ha
Period nEqiliter
PaCO2
mm
Hg
HCO3 HCO3C HCO3 Gap Na K C1 Pi Ca
mgldl
Protein
gidI
Creatinine
clearance
mI/mm
Weight
kgmEqiliter
Control vehicle infusion
37.0 37.8 25.6 25.6 12.4 140.4 4.2 106.6 3.6 9.3 6.6 141 73.7
±0.4 ±0.6 ±0.2 ±0.2 ±0.8 ±1.3 ±0.2 ±0.8 ±0.3 ±0.1 ±0.1 ±6 ±2.2
PTH infusion
Day 1 37.4 35.9 23.9 24.4a 10.7 138.1 4.1 107.6 3.4 boa 6.6 l25 73.7
±1.4 ±1.8 ±0.5 ±0.5 ±0.4 ±1.6 ±1.4 ±0.1 ±1.2 ±0.2 ±0.2 ±0.1 ±8 ±2.4
Day 2 39.0" 37.3 24.0" 24.V' —1.5 10.0 137.3 4.2 107.5 3.2 10,8b 6.7 733
±0.9 ±0.5 ±0.3 ±0.4 ±0.4 ±1.3 ±0.5 ±0.1 ±1.2 ±0.1 ±0.3 ±0.2 ±2.3
Days 3 36.7 37.5 25.6 25.7 +0.1 10.3 137.8 4.2 106.1 2.9 11.4" 6.9 73.1
through 6 ±0.5 ±0.6 ±0.1 ±0.1 ±0.1 ±1.2 ±1.1 ±0.1 ±0.7 ±0.2 ±0.4 ±0.2 ±2.4
Days 7 36.1 38.6 26.8 26.7" +1.1" 11.4" 139.5 4.2 105.6 2.9 120b 6.9 129 73.5
through 13 ±0.6 ±1.2 ±0.4 ±0.1 ±0.3 ±0.7 ±1.3 ±0.1 ±0.9 ±0.1 ±0.3 ±0.1 ±17 ±2.6
Recovery vehicle infusion
Day 1 35.3 37.8 26.9 26.9 +1.3 12.8 139.1 4.1 103.5" 2.9 9,6a 6.6a 74.1"
±0.7 ±0.9 ±0.6 ±0.5 ±0.6 ±0.9 ±0.7 ±0.1 ±0.4 ±0.2 ±0.6 ±0.2 ±2.7
Days 3 36.4 38.6 26.6 26.5 +0.9 11.9 139.5 4.1 105,1d 3,9a 93b 66b 131 74.4"
through 6 ±0.3 ±0.9 ±0.4 ±0.3 ±0.3 ±1.1 ±1.2 ±0.1 ±0.5 ±0.3 ±0.2 ±0.1 ±10 ±2.7
Day 8 35.2 35.3 25.2 25.7 +0.2 10.7 1376b 3.9 105.5 3.7 9.2 6.2 74.0"(N = 2) ±1.5 ±2.0 ±0.2 ±0.1 ±0.4 ±0.2 ±2.1 ±0.1 ±2.2 ±0.5 ±0.1 ±0.4 ±6.2
Abbreviations: Ha, hydrogen ion activity in arterialized blood; PaCO2, CO2 tension in arterialized blood.
Values are means ± 5EM; mean values were tested for significant differences from the previous steady-state period (Control or Days 7 to 13) and
are footnoted by a 1', and c indicative of significance at the 0.05, 0.01, and 0.001 probability levels, respectively, Values during the Recovery Period
were tested also for differences from the original Control Period and are footnoted by d , and indicative of significance at the 0.05, 0.01, and 0.001
probability levels, respectively (Student's t test). Corrected plasma [HC03} given as HCO3C is the value for plasma [HCO3] when the associated
PaCO2 value is adjusted to 37.8 mm Hg, the group control mean PaCO2 value, and a new [HCO3] calculated based on the slope of the [HCO3]
vs. PaCO2 relation for each period as given in Results. This corrected [HCO3-] thus reflects the [HCO3—} when variation due to respiratory factors
is removed from the total variation in [HCO3], which has both respiratory and nonrespiratory sources of variation [171.
tions. The studies were approved by the Institutional Review
Board, University of Florida, and informed consent was ob-
tained from each subject.
Studies were initiated by obtaining a 4- to 14-day prefeeding
period. During prefeeding and all subsequent periods of study,
each subject received a continuous intravenous vehicle infusion
at a rate of 50 ml/24 hr (0.45% NaCI/1% human serum albu-
min/0.01 M acetic acid, CorMed wearable pump, Medina, New
York, USA). During a control period of 5 to 7 days duration, a
steady state of plasma and urinary acid-base and electrolyte
composition was achieved. Following control, synthetic bPTH
(1—34) 6800 units/mg (Beckman, Palo Alto, California, USA)
was added to the infusate (6U/kg/24 hr) for a period of 12 to 13
days. Following the PTH infusion, a 4- to 8-day recovery period
was obtained (vehicle infusion).
All determinations were performed in duplicate. Analytical
methods used in this laboratory have been described in a
previous report [15]. Statistical analysis is by Student's t test,
linear regression analysis, and covariance analysis [161.
Results
Chronic intravenous infusion of PTH to normal subjects
resulted in persistent hypercalcemia (Fig. 1, Table 1). Plasma
bicarbonate concentration decreased sharply within 24 hr of
initiation of hormone administration and then increased pro-
gressively to values greater than control by the sixth day. A
significant initial increase in blood hydrogen ion concentration
was followed by a decrease below control levels. Plasma
anion gap was not significantly altered, indicating that transient
acidosis was hyperchloremic.
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Fig. 1. Effect of chronic PTH infusion on plasma acid-base and
electrolyte composition, urine pH, and net acid excretion. net acid
excretion reflects the daily difference from the mean control net acid
excretion value. Data are plotted as mean ± SEM (N = 4). On recovery
Days 5 and 7, N decreases to 3 and 2 for plasma data, respectively. On
recovery Days 4 and 7, N decreases to 3 and 2 for urine data,
respectively. Symbols are: 0, plasma Pi;•, plasma Ca and HCO3—;
, net acid excretion.
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Table 2. Effect of chronic PTH infusion on urinary acid-base and electrolyte excretion in human subjects (N = 4)
Net acid excretion decreased sharply on Day 1 of PTH
infusion as acidosis developed and increased subsequently as
alkalosis occurred (Fig. 1, Table 2). A mild, stable metabolic
alkalosis persisted during PTH Days 7 through 13. The impact
of respiratory versus metabolic factors in the observed stable
alkalosis was analyzed in Figure 2. Significant linear relations of
bicarbonate and hydrogen ion concentrations on PaCO2 were
obtained for each period in the present study as reported
previously by Madias et al [17] for control data in human
subjects. The findings of covariance analysis in Figure 2 indi-
cate that significantly increased and decreased steady-state
values of plasma bicarbonate and blood hydrogen ion concen-
trations during PTH infusion could not be accounted for by the
predictable changes that occur owing to PaCO2 variation,
namely, the observed changes were attributable to nonrespira-
tory or metabolic factors [17].
The cumulative increment in net acid excretion averaged 40
mEq by Day 8 and 55 mEq by the final day of PTH infusion.
Figure 3 depicts the highly significant positive correlation
between PTH-induced changes in plasma [HCO3] and the
cumulative change in net acid excretion during both acidosis
and steady-state alkalosis phases of response (linear regression
analysis). Net acid excretion returned to levels not different
from control in the steady state of alkalosis (Student's t test).'
Urine pH was reduced significantly in the steady-state period.
A significant cumulative increment in phosphate excretion
occurred during PTH infusion, which averaged 118 mmoles by
the final day of PTH. The cumulative sodium and potassium
deficits at the end of the PTH infusion period were identical and
averaged 39 mEq (Table 2).
The PTH-induced increase in plasma bicarbonate concentra-
tion returned to control levels during an 8-day recovery period,
in association with prompt normalization of plasma calcium and
phosphorus concentrations. The cumulative increment in net
acid excretion during PTH infusion (+55 mEq) was reversed
almost completely (—53 mEq) during the recovery period.
Discussion
The results of the present studies indicate that experimental
induction of a model of human primary hyperparathyroidism
achieved by chronic continuous infusion of parathyroid hor-
mone to normal subjects results in a biphasic renal and systemic
acid-base response. On the first day of PTH administration,
renal net acid excretion decreased and metabolic acidosis
occurred, which was followed by an increase in net acid
excretion and the development of a persistent mild metabolic
alkalosis. Sustained hormonal excess did not result in metabolic
acidosis as expected in clinical primary hyperparathyroidism
[1—5, 19].
Since significant increases in extrarenal bicarbonate genera-
tion have been observed in association with the presence of
PTH in experimental animals [11, 12], the possibility might be
considered that the observed PTH-induced increase (or absent
decrease) in steady-state plasma bicarbonate concentration
(Fig. 2, Table 1) is, at least in part, a secondary consequence of
TA Net C1
pH NH4 mEq/24 hr HC03 acid Pi
mmoles/24 hr
mmoles
Na K Ca mEq/24 hr
Volume
ml/24hrPeriod mEq mEq
Control vehicle infusion
6.65 25.4 8.7 20.3 13.8 21.3 116.2 95.6 9.5 119.7 3647
±0.02 ±1.1 ±0.4 ±1.2 ±1.3 ±0.8 ±3.1 ±1.7 ±0.7 ±2.8 ±41
PTH infusion
Day 1 695b 20.4a 7•4 44,6b 30.8" 165.3a 108.7" 8.7 124.9 3951
±0.06 ±3.0 ±1.3 ±4.5 ±5.1 ±2.0 ±11.3 ±1.0 ±0.9 ±12.2 ±181
Day 2 6.72 25.7 11.4 26.5 10.7 31.8a 147.6 90.7a 147b 131.2 3579
±0.06 ±5.5 ±1.6 ±6,5 ±6.8 ±1.4 ±6.4 ±2.6 ±2.3 ±3.5 ±155
Days 3 6.44" 28.4 15.5" 16.5 27.4" 31.0" 109.7 98.3 22.0" 122.7 3528
through 6 ±0.06 ±3.2 ±1.3 ±2.8 ±2.7 ±1.7 ±7.9 ±2.6 ±1.9 ±5.6 ±66
Days 7 6.51" 20.8 14.3" 16.3 18.8 29.8" 113.1 98.4 29.6" 118.9 3593
through 13 ±0.03 ±2.0 ±0.8 ±1.7 ±2.5 ±1.4 ±4.6 ±2.7 ±4.7 ±4.2 ±53
(Day 13, .) (—25) (+67") (—12) (+55) (1ll8b) (+39) (+39) (+190) (+27)
Recovery vehicle infusion
Day 1 6.43 21.3 6.6" 12.5 15.4 12,6b,a 88.1 80.7 28•1d 116.1 3Q43
±0.08 ±3.3 ±1.3 ±2.8 ±3.9 ±1.9 ±6.7 ±8.3 ±6.7 ±4.8 ±148
Days 3 6.57 20.2 7.7" 19.8 75t,,d 18.0" 113.5 90.6 9.6 113.8 3480
through 6 ±0.05 ±3.0 ±1.0 ±2.6 ±3.4 ±3.2 ±8.3 ±4.0 ±0.8 ±5.9 ±95
Day 8 6.00 19.6 15.9 9.0 26.5 24.3 126.2 107.4 6.1 122.8 3679(N = 2) ±0.34 ±2.4 ±2.7 ±2.6 ±2.9 ±1.1 ±3.0 ±0.9 ±1.8 ±9.5 ±24(Day 6, ) (+9) (41a) (+l6 (—53) (—79") (_67a) (—58) (—67") (—45)
Values are means ± SEM; mean excretion values were tested for significant differences from the previous steady-state period (Control period or
Days 7 to 13 of PTH) and are footnoted by a, b, and" indicative of significance at the 0.05, 0.01, and 0.001 probability levels, respectively. Excretion,
values during the Recovery Period were tested also for differences from the original Control Period and are footnoted by d and indicative of
significance at the 0.05, 0.01, and 0.001 probability levels, respectively (Student's r test). Urinary excretion values are normalized to 70kg body
wt. Cumulative excretion values (.A) are calculated as the accumulated sum of the daily differences from the previous steady-state period and
are depicted by parentheses. For £ values, the symbols refer to significant differences from zero.
'The control mean net acid excretion value of 14 mEq/24 hr is within the
range of values reported for normal subjects ingesting a nearly identical
diet [Diet A, 18]. However, the higher mean value of 27 mEq/24 hr in
the previous report may reflect augmented net alkali absorption from
the intestine in the present studies owing to the CaCO3 supplement.
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Fig. 2. Relations of blood hydrogen ion concentration to PaCO2 and
plasma bicarbonate concentration to PaCO2 during control and PTH
infusion (Days 7 through 13) steady-state periods. In both relations, the
slopes were not significantly different between periods, P > 0.10, P>
0.15, respectively. However, the elevations at the midpoint PaCO2
differed significantly between periods, P < 0.001, P < 0.01, respec-
tively. Symbols are: (Upper panel) •, control group (y = 10.8 + 0.69x,
r = 0.83, P < 0.001; 0, PTH group, days 7 through 13 (y = 14.4 +
0.56x, r = 0.87, P <0.001. (Lower panel) I, control group (y = 18.9 +
0.18x, r 0.61, P <0.001; 0, PTH group, days 7 through 13 (y = 16.8
+ 0.26x, r = 0,65, P <0.001.
an augmented and sustained increase in extrarenal alkali release
to ECF. This possibility is excluded by the observation that in
the steady-state of PTH-induced hyperbicarbonatemia (Days 7
through 13), the daily net systemic acid load requiring renal
excretion was not significantly different from control. Thus, in
the steady-state period of PTH infusion, the "set point" for
renal regulation of plasma bicarbonate concentration has been
increased, since plasma bicarbonate concentration was in-
creased despite no change in effective endogenous acid produc-
tion as reflected in an unchanged daily net acid excretion rate.
The present results demonstrate also that the kidney is respon-
sible in part for the generation of metabolic alkalosis inasmuch
as a cumulative increment in net acid excretion was observed
during PTH administration. Based on a space of distribution for
bicarbonate of 50% body wt, a 70 kg subject would require a
cumulative increment in net acid excretion of 42 mEq to
account for the observed increment in steady-state plasma
bicarbonate concentration (1.2 mEq/liter), a value in close
agreement with the observed value of 55 mEq. Further evi-
dence for a renal mechanism is the similar, but directionally
opposite, cumulative change in net acid excretion and change in
plasma bicarbonate concentration observed following
discontinuation of PTH administration. Also, renal mechanisms
appear to account for the transient metabolic acidosis observed
in the initial period of PTH administration inasmuch as net acid
excretion decreased significantly in close temporal correlation
with the observed nadir value for plasma bicarbonate concen-
tration (Day 1). The highly significant positive correlation
observed between changes in plasma bicarbonate concentration
and changes in net acid excretion (Fig. 3). provides strong
evidence for a renal mechanism as the major determinant of
both transient acidosis and sustained alkalosis. This finding,
however, does not exclude the operation of extrarenal factors
that might either attentuate or accentuate the generation phase
of both disorders.
The finding of a transient mild PTH-induced hyperchioremic
acidosis in the present studies is consistent with previous
results in both humans and experimental animals that acute
bicarbonaturia and/or suppression of net acid excretion results
from acute PTH administration [20—23]. An acute suppression
of renal acidification caused by PTH is consistent with results of
both in vivo micropuncture studies in rats and dogs and isolated
perfused tubule studies in rabbits that have demonstrated
PTH-induced inhibition of proximal bicarbonate reabsorption
[6—101. The observed transient acidosis is consistent also with
reports of this disorder in clinical cases of hyperparathyroidism
[1—5].
The present finding of a persisting steady-state stimulation of
renal acidification characterized by a stable glomerular filtration
rate, increase in plasma bicarbonate concentration, mild
alkalemia, a decrease in steady-state urine pH, and an increased
cumulative change in net acid excretion rate is inconsistent with
previous reports of persistent metabolic acidosis in primary
hyperparathyroidism. However, PTH administration has been
reported to stimulate net acid excretion in both an acute [61 and
chronic time course in experimental animals [13, 14]. Additional
support for the occurrence of PTH-induced stimulation of distal
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Fig. 3. Relation of PTH-induced change in mean plasma [HCO3"] and
the cumulative change in net acid excretion during each of 13 days of
PTH infusion in human subjects (N = 4) (y = 0.27 + 0.038x, r = 0.97,
P <0.001.)
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nephron acidification is the finding that PTH significantly in-
creased transepithelial hydrogen ion secretion in a model of the
mammalian distal nephron, the isolated urinary bladder of the
Colombian toad [24]. Chronic PTFI-induced metabolic alkalosis
has been reported in both rats and dogs [13, 14, 25, 26] and the
studies in both species have demonstrated that renal mecha-
nisms account, at least in part, for both the generation and
maintenance of the alkalosis [13, 14]. The chronic studies in
TPTX dogs [13, 14] and intact rats [261 have documented that
persistent (2-week) PTFI administration (dogs) or multiple
autologous parathyroid gland grafts (rats) results in an increase
in the cumulative change in net acid excretion and establish-
ment of a new steady state of acid-base equilibrium in which net
acid excretion returns to control values and plasma bicarbonate
concentration remains elevated. PTH-induced alkalosis in in-
tact dogs is similar in that hyperbicarbonatemia is maintained
by the kidney, but dissimilar in that renal mechanisms do not
account fully for the generation of the disorder [13, 14].
The possible role of hypercalcemia in mediating alkalosis is
not excluded by the present studies. This important possibility
is supported by the finding that acute elevation of plasma
calcium concentration enhances renal bicarbonate reabsorptive
capacity and increases net acid excretion in dogs [27, 28].
However, two lines of evidence argue against hypercalcemia as
the determinant of chronic alkalosis in the present studies.
First, metabolic alkalosis maintained by renal mechanisms has
been described in a canine model of EGTA-induced chronic
hypocalcemic hyperparathyroidism [14]. Second, chronic
hypercalcemia produced by continuous intravenous calcium
infusion in dogs has been reported to result in metabolic
acidosis, possibly owing to extrarenal loss (for example, pre-
cipitation) of calcium-containing alkali salts from ECF [13].
Since transient small increases in urinary sodium, potassium,
and chloride excretion were observed during the first two days
of PTH infusion, it is possible that the associated small but
persistent degree of ECF volume contraction contributed to the
subsequent development and maintenance of metabolic
alkalosis. However, the observation that after alkalosis devel-
oped chloride excretion was stable and approximated a quanti-
tatively generous chloride intake is evidence that the observed
metabolic alkalosis was "chloride resistant," that is, not de-
pendent on deficient chloride intake or systemic load of chlo-
ride. Indeed, since hyperbicarbonatemia in the present studies
was associated with a chioruresis and a tendency to
hypochioremia in the steady-state of PTH infusion, it is possible
that the observed increase in set point for renal regulation of
plasma bicarbonate concentration (chronic hyperbicarbonate-
mia without a decrease in steady-state systemic acid load
requiring renal excretion) is a reflection of a primary decrease in
the set point for renal regulation of plasma chloride concentra-
tion. It is possible that PTH-induced hypercalcemia caused a
specific defect in renal chloride transport in the ioop of Henle
[29]. The associated possibility that the small potassium deficit
of 39 mEq that accumulated during the PTH period (20 mEq by
Day 6 when hyperbicarbonatemia was established) might have
had pathogenetic significance in the development of alkalosis
seems very unlikely, inasmuch as no tendency to hypokalemia
was observed despite the presence of alkalosis.
In summary, the present results demonstrate that experimen-
tally induced primary hyperparathyroidism in humans results in
transient renal acidosis, followed by a steady state of mild
metabolic alkalosis caused and maintained, at least in part, by
renal mechanisms when examined over a 13-day period. PTH-
induced renal alkalosis is reversible almost totally over an 8-day
recovery period. The finding of mild metabolic alkalosis in the
present studies contrasts with clinical reports of hyper-
chioremic acidosis in human primary hyperparathyroidism of
presumed longer duration. Further studies are required to
elucidate whether single or multiple potential acidosis-produc-
ing factors associated with long-term clinical hyperpara-
thyroidism (for example, nephrocalcinosis, renal insufficiency,
nephrosclerosis, overproduction of additional hormones) might
override the sustained renal alkalosis-producing effect of PTH
demonstrated in the present studies.
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